Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

576.60INR
21 Jul 2017
Change (% chg)

-- (--)
Prev Close
Rs576.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
487,101
52-wk High
Rs854.50
52-wk Low
Rs493.00

Latest Key Developments (Source: Significant Developments)

Beijing Science Sun Pharmaceutical sees H1 FY 2017 net profit down 10 pct to 25 pct
Thursday, 13 Jul 2017 03:17am EDT 

July 13(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ> ::* Sees H1 FY 2017 net profit to decrease by 10 percent to 25 percent, or to be 98.9 million yuan to 118.6 million yuan.* Says H1 FY 2016 net profit was 131.8 million yuan.* The reasons for the forecast are decreased bid price and policy effect .  Full Article

Sun Pharmaceutical Industries announces manufacturing tie-up with Samsung Biologics
Monday, 3 Jul 2017 10:52pm EDT 

July 4 (Reuters) - Sun Pharmaceutical Industries Ltd ::Strategic manufacturing tie-up with Samsung Biologics for Tildrakizumab.Unit, Samsung Biologics to manufacture Tildrakizumab.Drug is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.Approximate value of the contract will be US$ 55.5 million.  Full Article

Beijing Science Sun Pharmaceutical succeeds in its bid to buy 45 pct stake in Beijing Protein Innovation
Tuesday, 27 Jun 2017 01:36am EDT 

June 27 (Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ> ::* Says it has been successful in its bid to acquire 45 percent stake in Beijing Protein Innovation with final transaction price of 22 million yuan .  Full Article

Sun Pharma Industries gets members' nod for scheme of arrangement with Sun Pharma Medisales, Ranbaxy Drugs, others
Wednesday, 21 Jun 2017 11:01pm EDT 

June 22 (Reuters) - Sun Pharmaceutical Industries Ltd :Gets members' nod for scheme of arrangement among Sun Pharma Medisales, Ranbaxy Drugs, Gufic Pharma, Vidyut Investments, co.  Full Article

Beijing Science Sun Pharmaceutical to buy 45 pct stake in Beijing Protein Innovation
Thursday, 15 Jun 2017 03:05am EDT 

June 15(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ> ::* Says it will buy 45 percent stake in Beijing Protein Innovation no less than 22 million yuan.  Full Article

Sun Pharmaceutical Industries says US FDA approval for generic zetia tablets
Monday, 12 Jun 2017 10:44pm EDT 

June 13 (Reuters) - Sun Pharmaceutical Industries Ltd :Says Sun Pharma announces US FDA approval for generic zetia tablets.Says generic ezetimibe tablets are therapeutic equivalents of Merck's Zetia® tablets.  Full Article

Sun Pharma may have single digit decline in consol revenue for FY 18 vs FY 17 - exec
Friday, 26 May 2017 09:07am EDT 

May 26 (Reuters) - Sun Pharmaceutical Industries Ltd :Dilip Shanghvi says may have single digit decline in consol revenue for FY 18 versus FY 17.Dilip Shanghvi says "FY18 is likely to be a challenging year for us".Dilip Shanghvi says co took $45 million u.s. Inventory related charge in Q4 that is unlikely to be recurring.Dilip Shanghvi says co awaiting FDA inspection on Halol, unaware of FDA’s stance on the facility.Dilip Shanghvi says value of first-to-file products even during exclusivity is likely to go down.  Full Article

India's Sun Pharmaceutical Industries March-qtr consol profit down about 14 pct
Friday, 26 May 2017 07:16am EDT 

May 26 (Reuters) - Sun Pharmaceutical Industries Ltd :March quarter consol net profit 12.24 billion rupees.Consensus forecast for March quarter consol profit was 14.95 billion rupees.March quarter consol total revenue from operations 71.37 billion rupees.Consol net profit in March quarter last year was 14.16 billion rupees as per Ind-AS; consol total revenue from operations was 76.54 billion rupees.Recommended dividend of 3.50 rupees per share.Says reappointment of Dilip Shanghvi as MD.Says resignation of Uday Baldota as CFO.  Full Article

Sun Pharma announces fda filing acceptance of Biologics License Application for tildrakizumab
Wednesday, 24 May 2017 08:03am EDT 

May 24 (Reuters) - Sun Pharmaceutical Industries Ltd : :Sun Pharma announces U.S. FDA filing acceptance of Biologics License Application (bla) for tildrakizumab.  Full Article

Sun Pharma says US FDA files acceptance of BLA for Tildrakizumab
Wednesday, 24 May 2017 12:55am EDT 

May 24 (Reuters) - Sun Pharmaceutical Industries Ltd :Says US FDA filing acceptance of biologics license application (BLA) for Tildrakizumab.Says Tildrakizumab is investigational IL-23P19 inhibitor evaluated for treatment of moderate-to-severe plaque psoriasis..  Full Article